The Maviret from AbbVie Inc. - oral hepatitis C therapy now extended to acute cases
28.06.2026 - 07:31:00 | ad-hoc-news.de
Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 07:30. Details in the imprint.
The Maviret sits on a white dispensing tray, three small tablets that many hepatitis C patients now take once daily instead of facing weeks of injections. The blister foil feels stiff and clinical, but for long-time patients this regimen can be quietly reassuring.
How Maviret works in daily use
Maviret is an oral, pangenotypic direct-acting antiviral therapy that combines glecaprevir and pibrentasvir in a fixed-dose tablet taken with food once daily. It targets all major hepatitis C virus genotypes and is designed for short treatment courses, often 8 to 12 weeks, in chronic infection.
For patients, that means fewer hospital visits and a cleaner daily routine, with many able to swallow the small tablets at breakfast and continue with work or school. Hepatologist Dr. Anil Patel describes the regimen as "tidy and practical" compared with older interferon-based therapies.
New approval for acute hepatitis C
AbbVie recently secured a European Commission approval that extends the label of Maviret to include acute hepatitis C virus infection in adults and children from 3 years of age. This broadens its use beyond chronic cases and gives physicians a more flexible tool early in the disease course.
According to AbbVie, the updated indication covers all major genotypes, and pediatric dosing is weight-based to keep exposure consistent across age groups. Pediatric hepatologists welcome having an oral option for children who otherwise might face more invasive regimens.
Background on AbbVie Inc. shares
Pipeline updates such as the Maviret label extension regularly shape how investors view AbbVie Inc. and its long-term earnings power.
Position in AbbVie’s portfolio
For AbbVie, Maviret sits alongside immunology blockbusters like Humira and Skyrizi as part of a broader specialty pharma portfolio. Chief executive Richard A. Gonzalez has repeatedly highlighted virology as one of the company’s consistent cash-flow pillars in investor presentations.
The regimen competes with other direct-acting antivirals but differentiates itself with short-course treatment and pangenotypic coverage, which can simplify formulary decisions for payers. That combination keeps the product relevant even as newer therapies emerge.
Where Maviret is available
Maviret is marketed primarily in Europe and North America, with reimbursement schemes varying by country and insurance system. In the EU it is available through hospital pharmacies and specialist clinics, typically after prescription by hepatologists or infectious-disease specialists.
Germany-based patients usually access Maviret within statutory health insurance frameworks once treatment is approved by a specialist center. Outside Europe, regulators such as the FDA and Health Canada also oversee local indications and dosing guidelines, making the product a global fixture in hepatitis C care.
Context for AbbVie shares
For investors, Maviret is part of the established, cash-generating segment that helps balance AbbVie’s newer launches in immunology and aesthetics. AbbVie Inc. shares (ISIN US00287Y1091) trade on the New York Stock Exchange in US dollars as one of the larger US pharma constituents.
Key facts on Maviret
- Product: Maviret (glecaprevir/pibrentasvir)
- Manufacturer: AbbVie Inc.
- Category: Classic long-term therapy for hepatitis C
- Launch: Initially approved for chronic hepatitis C in adults, with later extensions including acute infection and pediatric use in Europe.
- RRP / Price: Typically reimbursed via national health systems or private insurance; list prices vary by country and contract.
- Availability: Specialist prescription through hospital and clinic pharmacies in Europe, North America and selected other markets.
- Target group: Adults and children from 3 years of age with chronic or acute hepatitis C virus infection.
- Highlight / USP: Oral, pangenotypic, short-course regimen covering both chronic and acute hepatitis C with pediatric indications.
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
